Citius Oncology Inc (CTOR)

Mar 15, 2025

Citius Oncology, Inc. (NASDAQ:CTOR) Is Expected To Breakeven In The Near Future - simplywall.st

Mar 15, 2025

Mar 07, 2025

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financia - GuruFocus.com

Mar 07, 2025

Feb 18, 2025

Citius Pharma's LYMPHIR gains permanent J-code for billing - MSN

Feb 18, 2025

Feb 15, 2025

Citius Oncology (NASDAQ:CTOR) Issues Earnings Results - MarketBeat

Feb 15, 2025

Feb 15, 2025

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve

Feb 15, 2025

Feb 14, 2025

Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update - 69News WFMZ-TV

Feb 14, 2025

Feb 14, 2025

Citius Oncology Inc. (CTOR) reports earnings - Quartz

Feb 14, 2025

Feb 14, 2025

CITIUS ONCOLOGY, INC. SEC 10-Q Report - TradingView

Feb 14, 2025

Feb 14, 2025

Citius Oncology Preps LYMPHIR Cancer Drug Launch While Strategic Review Unfolds - StockTitan

Feb 14, 2025

Feb 08, 2025

Citius Pharmaceuticals (NASDAQ:CTXR) Announces Issuance of Permanent J-Code for LYMPHIR by CMSOn February 6, 2025, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) disclosed in an 8-K filing that the company and its oncology subsidiary, Citius Oncol - Defense World

Feb 08, 2025

Feb 07, 2025

Citius Pharma’s LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Nigeria

Feb 07, 2025

Feb 06, 2025

Citius Pharma's LYMPHIR gains permanent J-code for billing By Investing.com - Investing.com Australia

Feb 06, 2025

Feb 06, 2025

Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance CodeMajor Win for CTCL Patients - StockTitan

Feb 06, 2025

Feb 02, 2025

Citius Oncology (NASDAQ:CTOR) Shares Down 2%Here's What Happened - MarketBeat

Feb 02, 2025

Jan 27, 2025

Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow

Jan 27, 2025

Jan 15, 2025

Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - 69News WFMZ-TV

Jan 15, 2025

Jan 09, 2025

Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World

Jan 09, 2025

Jan 08, 2025

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - BioSpace

Jan 08, 2025

Jan 08, 2025

Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan

Jan 08, 2025

Jan 07, 2025

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire

Jan 07, 2025

Jan 07, 2025

Citius Oncology to explore strategic alternatives - Yahoo Finance

Jan 07, 2025

Jan 06, 2025

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve

Jan 06, 2025

Jan 06, 2025

I-Mab stops work on CD73; Citius to pursue ‘strategic’ options - Endpoints News

Jan 06, 2025

Jan 01, 2025

Citius Pharma Reports 2024 Financial Results and Business Update - MSN

Jan 01, 2025

Dec 31, 2024

Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance

Dec 31, 2024

Dec 29, 2024

Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World

Dec 29, 2024

Dec 28, 2024

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve

Dec 28, 2024

Dec 27, 2024

Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com

Dec 27, 2024

Dec 27, 2024

Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz

Dec 27, 2024

Dec 17, 2024

Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com

Dec 17, 2024

Dec 07, 2024

Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register

Dec 07, 2024

Dec 06, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online

Dec 06, 2024

Dec 03, 2024

“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart

Dec 03, 2024

Dec 03, 2024

Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Dec 03, 2024

Dec 01, 2024

Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World

Dec 01, 2024

Nov 29, 2024

Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St

Nov 29, 2024

Nov 28, 2024

Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance

Nov 28, 2024

Nov 26, 2024

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com

Nov 26, 2024

Nov 26, 2024

Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com

Nov 26, 2024

Nov 25, 2024

Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan

Nov 25, 2024

Nov 23, 2024

CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada

Nov 23, 2024

Nov 22, 2024

CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa

Nov 22, 2024